MedTrace Logo

Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb

NCT04462445 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-07-10

No results posted yet for this study

Summary

This is a prospective, single-arm, monocentric translational study designed to evaluate possible biomarkers of resistance to the first line of therapy with pazopanib in patients with metastatic renal cell carcinoma (mRCC) who have not received systemic therapy in both the adjuvant and metastatic phases.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Pazopanib

Sponsors & Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Principal Investigators

  • Giuseppe Procopio, MD · Fondazione IRCCS ISTITUTO NAZIONALE TUMORI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-25
Primary Completion
2017-02-08
Completion
2017-02-08

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04462445 on ClinicalTrials.gov